Cue Biopharma (CUE) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO, with formal roles assigned for presiding officer, inspector of election, and secretary.
Meeting conducted virtually, with procedures for participation and voting explained.
Forward-looking statements disclaimer provided, referencing risk factors in recent SEC filings.
Specific resolutions to be voted on
Approval of issuance of common stock upon exercise of warrants related to a May 2026 licensing transaction and private placement.
Approval of the 2026 Stock Incentive Plan.
Approval to adjourn the meeting if necessary to solicit further proxies for the above proposals.
Corporate governance
Record date for stockholders set as May 8, 2026, with notice and affidavit filed.
Quorum confirmed by inspector of election, allowing business to proceed.
Voting rules and procedures outlined, including proxy voting and board recommendations.
Latest events from Cue Biopharma
- Advancing dual-mechanism immunotherapies with major clinical milestones expected by end of 2026.CUE
Jefferies Global Healthcare Conference 20263 Jun 2026 - Registering 4.1M shares for resale after $30M private placement; proceeds only from warrant exercises.CUE
Registration filing3 Jun 2026 - Approval sought for share issuance, new incentive plan, and meeting adjournment authority.CUE
Proxy filing21 May 2026 - Revenue up, net loss down, and new financing extends runway into 2027, but capital needs persist.CUE
Q1 202614 May 2026 - Shareholders to vote on major share issuance, new incentive plan, and meeting adjournment authority.CUE
Proxy filing12 May 2026 - All proposals, including a reverse stock split, were approved at the virtual meeting.CUE
AGM 202613 Apr 2026 - Advancing to Phase 1, the bifunctional therapy targets autoimmune diseases with strong preclinical data.CUE
R&D Day 202613 Apr 2026 - Director resignation leads to interim CEO appointment and board size reduction.CUE
Proxy filing27 Mar 2026 - Biotech seeks up to $300M in securities amid going concern risk and ongoing capital needs.CUE
Registration Filing17 Mar 2026